Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2010

01-08-2010 | Adis Drug Profile

Oral Bepotastine

In Allergic Disorders

Author: Katherine A. Lyseng-Williamson

Published in: Drugs | Issue 12/2010

Login to get access

Abstract

Oral bepotastine is a second-generation histamine H1 receptor antagonist that also suppresses some allergic inflammatory processes.
Numerous short- and long-term clinical trials and surveillance studies have shown that twice-daily bepotastine is an effective and generally well tolerated antihistamine in the treatment of patients with allergic rhinitis, chronic urticaria or pruritus associated with skin conditions (eczema/dermatitis, prurigo or pruritus cutaneus).
Bepotastine 20 mg/day was significantly more effective than terfenadine 120 mg/day in patients with perennial allergic rhinitis, as evaluated by the final global improvement rating and several other endpoints in a phase III trial.
In phase III trials in patients with chronic urticaria, bepotastine 20 mg/day was more effective than placebo in improving levels of itching and eruption, and as effective as terfenadine 120 mg/day with regard to the final global improvement rating and other endpoints.
In a noncomparative trial in patients with pruritus associated with skin diseases, the majority of bepotastine recipients in the overall population, as well as in the specific skin disease subgroups (eczema/dermatitis, prurigo or pruritus cutaneus), had a final global improvement rating of moderate or greater.
Bepotastine was generally well tolerated in adult and paediatric patients with allergic conditions.
Literature
1.
Bousquet J, Reid J, van Weel C, et al. Allergic rhinitis management pocket reference 2008. Allergy 2008; 63(8): 990–6CrossRefPubMed
2.
Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GAL2EN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64(10): 1427–43CrossRefPubMed
3.
Furukawa F. Atopic dermatitis and urticaria: for the prevention and cure via disease control and management [in Japanese]. Nippon Rinsho 2009 Nov; 67(11): 2152–6PubMed
4.
Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006; 118(5): 985–96CrossRefPubMed
5.
Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108(2): S65–71CrossRefPubMed
6.
Talion® tablets (bepotastine besilate): product information. Osaka: Tanabe Seiyaku Co., Ltd, 2006
7.
Ishibashi Y, Kawashima M, Harada S, et al. Phase I study of antiallergic agent, TAU-284 (betotastine besilate): study of inhibitory effect on intradermal reaction of histamine [in Japanese]. Rinsho Iyaku 1997; 13(5): 1187–97
8.
Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol 2004 Sep; 29(5): 526–32CrossRefPubMed
9.
Tashiro M, Duan X, Kato M, et al. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol 2008 Jun; 65(6): 811–21CrossRefPubMedPubMedCentral
10.
Yokota H, Mizuuchi H, Maki T, et al. Phase I study of TAU-284: single oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1997; 13(5): 1137–53
11.
Kadosaka T, Shiraishi K, Mizuuchi H, et al. Phase I study of TAU-284: repeated oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1997; 13(5): 1155–68
12.
Kumagai Y, Uchiumi M, Murasaki M, et al. Pharmaco-kinetics study of TAU-284 in elderly volunteers [in Japanese]. Rinsho Iyaki 1997; 13(5): 1169–85
13.
Hashiguchi K, Tang H, Fujita T, et al. Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO chamber). Expert Opin Pharmacother 2009 Mar; 10(4): 523–9CrossRefPubMed
14.
Ohta N, Akatsuka N, Saito F, et al. The effect of prophylactic treatment with bepotastine in patients with Japanese cedar pollinosis [in Japanese]. Pract Oto Rhino Laryngol 2002; 95(5): 531–7CrossRef
15.
Ukai K, Takeuchi M, Masuda S, et al. Clinical pharmacological study of antiallergic agent, TAU-284 (betotastine besilate): the effect on counting of eosinophils in nasal discharge and the patency improvement of nasal cavity [in Japanese]. Rinsho Iyaku 1997; 13(5): 1401–12
16.
Kawashima K, Sakai M, Takatsuka S, et al. Clinical pharmacokinetic study of Talion® tablet (bepotastine besilate) in nephropathic patients (post-marketing clinical trial) [in Japanese]. Rinsho Iyaku 2003; 19(6): 637–48
17.
Kato M, Nishida A, Aga Y, et al. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. Arzneimittelforschung 1997 Oct; 47(10): 1116–24PubMed
18.
Yato N, Murata T, Saito N, et al. Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug [in Japanese]. Nippon Yakurigaku Zasshi 1997 Jul; 110(1): 19–29CrossRefPubMed
19.
Ueno M, Inagaki N, Nagai H, et al. Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen. Pharmacology 1998 Oct; 57(4): 206–14CrossRefPubMed
20.
Honda H. Inhibitory effect of betotastine on anaphylactic and histamine-induced reactions in guinea pigs [in Japanese]. Jpn Pharmacol Ther 1997; 25(4): 9–18
21.
Sakamoto O, Okanari E, Ueno H. Effect of betotastine on experimental asthma induced in guinea pigs [in Japanese]. Jpn Pharmacol Ther 1997; 25(4): 19–24
22.
Murata T, Matsumoto Y, Suzuki T, et al. Effect of betotastine besilate (TAU-284), a novel anti-allergic agent on experimental allergic rhinitis [in Japanese]. Jpn J Allergol 1997; 46(7): 576–84
23.
Andoh T, Kuraishi Y. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol 2006 Oct 10; 547(1-3): 59–64CrossRefPubMed
24.
Tanizaki H, Kambe N, Nakamura Y, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol 2008; 145(4): 277–82CrossRefPubMed
25.
Sakai A, Kikuchi M, Yato N, et al. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 1997 Aug; 47(8): 954–8PubMed
26.
Shin’ichi S, SangJae B, Fumihide O. Bepotastine besilate suppresses ICAM-1 expression in vascular endothelial cells [in Japanese]. Jpn J Clin Exp Med 2006; 83(8): 1245–8
27.
SangJae B, Shin’ichi S. Suppression effect of bepotastine besilate on oxidative stress (nitric acid: NO) [in Japanese]. Jpn J Clin Exp Med 2008; 85(7): 1045–8
28.
Kaminuma O, Ogawa K, Kikkawa H, et al. A novel antiallergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol Pharm Bull 1998 Apr; 21(4): 411–3CrossRefPubMed
29.
Kobayashi M, Kabashima K, Nakamura M, et al. Down-modulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes. Skin Pharmacol Physiol 2009; 22(1): 45–8CrossRefPubMed
30.
Ohashi R, Kamikozawa Y, Sugiura M, et al. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 2006 May; 34(5): 793–9CrossRefPubMed
31.
Baba S, Takasaka T, Baba K, et al. Clinical trial of TAU-284 (betotastine besilate) on perennial allergic rhinitis: a double-blind study in comparison with terfenadine [in Japanese]. Rinsho Iyaku 1997; 13(5): 1307–35
32.
Kawashima M, Harada S, Nakashima M, et al. Phase III study of TAU-284 (bepotastine besilate) on chronic urticaria: a multicenter double-blind comparative study with placebo [in Japanese]. Rinsho Iyaku 2002; 18(4): 501–19
33.
Ishibashi Y, Harada S, Niimura M, et al. A multicenter double-blind comparative study; clinical evaluation of TAU-284 (betotastine besilate) on chronic urticaria using terfenadine as a control drug [in Japanese]. Rinsho Iyaku 1997; 13(5): 1287–306
34.
Ishibashi Y, Harada S, Niimura M, et al. Clinical evaluation of TAU-284 (betotastine besilate) on eczema/dermatitis, prurigo, and pruritus cutaneus [in Japanese]. Rinsho Iyaku 1997; 13(5): 1383–400
35.
Baba S, Sakakura Y, Iwata S, et al. Early phase II study of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku 1997; 13(5): 1217–35
36.
Baba S, Takasaki T, Baba K, et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis: dose finding study by the double-blind method [in Japanese]. Rinsho Iyaku 1997; 13(5): 1259–86
37.
Ishibashi Y, Harada S, Niimura M, et al. Early phase II study of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. Rinsho Iyaku 1997; 13(5): 1199–215
38.
Ishibashi Y, Harada S, Niimura M, et al. Late phase II study of TAU-284 (betotastine besilate) on chronic urticaria: optimal dose finding study by double-blind technique [in Japanese]. Rinsho Iyaku 1997; 13(5): 1237–57
39.
Baba S, Takasaka T, Baba K, et al. Long-term treatment of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku 1997; 13(5): 1361–82
40.
Ishibashi Y, Harada S, Niimura M, et al. Long-term treatment of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. Rinsho Iyaku 1997; 13(5): 1337–59
41.
Baba K. Results from post-marketing surveillance studies of Talion® tablets (bepotastine besilate) in patients with allergic rhinitis [in Japanese]. J New Rem Clin 2007 Feb 10; 56 (2 Suppl.): 10–33
42.
Baba S. Post-marketing surveillance study of Talion® tablets on pediatric allergic rhinitis [in Japanese]. Rinsho Iyaku 2002; 18(12): 1371–87
43.
Kawashima M. Post-marketing surveillance of Talion® tablets (bepotastine besilate) in patients with urticaria and pruritus associated with skin disease (eczema/dermatitis, prurigo, and cutaneous pruritus) [in Japanese]. J New Rem Clin 2007; 56(8): 93–107
44.
Kohda F, Furue M, Imafuku S. Immediate clinical effectiveness of bepotastine besilate for patients with urticaria [in Japanese]. Nishinihon J Dermatol 2006; 68(5): 544–7CrossRef
45.
Kubota Y, Moriue T, Nakai K, et al. Effects of bepotastine besilate on clinical usefulness with chronic urticaria based on patient-centered evaluation and patients’ QOL [in Japanese]. Nishinihon J Dermatol 2007; 69(5): 554–60CrossRef
46.
Dainichi T, Furue M, Murota H, et al. Assessment of the therapeutic effect of bepotastine besilate on chronic urticaria using a visual analogue scale (VAS) [in Japanese]. Skin Res 2007; 6(5): 513–8
47.
Furumura M, Kubota Y, Nakayama J. Efficacy and safety of bepotastine besilate in the treatment of chronic urticaria [in Japanese]. Nishinihon J Dermatol 2006; 68(1): 69–75CrossRef
48.
Horikawa T, Ueda M, Nishigori C, et al. Efficacy of bepotastine besilate in the management of senile pruritic diseases [in Japanese]. Skin Res 2005; 4(5): 475–80
49.
Takahashi H, Iizuka H. Usefulness and safety of bepotastine besilate for pruritic skin disorders [in Japanese]. Nishinihon J Dermatol 2006; 68(3): 284–7CrossRef
Metadata
Title
Oral Bepotastine
In Allergic Disorders
Author
Katherine A. Lyseng-Williamson
Publication date
01-08-2010
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2010
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11205880-000000000-00000

Other articles of this Issue 12/2010

Drugs 12/2010 Go to the issue

Current Opinion

Drug or Vaccine?

Adis Drug Profile

Roflumilast

Therapy in Practice

Laxative Abuse

Adis Drug Profile

Oral Colchicine (Colcrys®)

Adis Drug Profile

Dexlansoprazole Modified Release

Adis Drug Evaluation

Inactivated Split-Virion Seasonal Influenza Vaccine (Fluarix®)